We’re ScreenPoint Medical

  • Bringing AI to the fight against breast cancer
    Bringing AI to the fight against breast cancer

We’re ScreenPoint Medical

We are bringing AI to the fight against breast cancer with leading clinical evidence and the latest deep learning technology.

We’re ScreenPoint Medical

See why users trust Transpara

In the decade since its founding, ScreenPoint and its flagship product Transpara have helped thousands of radiologists and supported care for millions of women with a relentless focus on improving workflow, increasing confidence and delivering clinically and operationally relevant results. That’s why users trust Transpara.

We are now prospectively implementing Transpara in our screening program and we are very excited to see the results from our prospective trial. Even better, we have observed that the latest version of Transpara has significantly improved the detection performance of the system, and a higher sensitivity is achieved at high specificity.
Dr Alvarez Benito
Dr Alvarez Benito
Consultant Radiologist, Hospital Universitario Reina Sofia in Cordoba, Spain
We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists.
Hakan-1
Håkan Gustafsson
Deputy Director CMIV, AI Coordinator at Region Östergötland
Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources.
 Sylvia H Heywang-Köbrunner
Professor Sylvia H Heywang-Köbrunner
Radiologist, Head of the Referenzzentrum Mammographie Munich, Germany
Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram.
Dr. Brian Englander, MD
Dr. Brian Englander, MD
Robert E. Campbell Professor of Clinical Radiology, Perelman School of Medicine Chairman, Department of Radiology, Pennsylvania Hospital Penn Center for Global Health Scholar
I use Transpara all the time, and won’t read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology’s score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster.
Dr. Daniel Gurrell, MD
Dr. Daniel Gurrell, MD
Vice President and Associate Medical Director at University Diagnostic Medical Imaging P.C.USA
Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their Intuitive Triage software.
Dr. Roger Yang, MD, FACR
Dr. Roger Yang, MD, FACR
President, University Radiology Group

Our partners, your workflow

Improve patient outcomes

At ScreenPoint, we know that breast imaging – and particularly breast screening – cannot function without effective workflow. To support our customers, we have designed an offering that is flexible and environment agnostic. Transpara works on 2D and 3D acquisitions, and our detection algorithm works on gantries from every major manufacturer. Regardless of your workflow, we want to fit seamlessly into your toolkit, so we work hard to ensure a seamless integration regardless of acquisition and reading environments.

See why users trust Transpara

Research Grants & Funding

Our commitment to advancing breast cancer detection is supported by leading research grants. These funds allow us to drive innovation, enhance clinical outcomes, and collaborate with top research institutions.

The “Autonomous AI for Cancer Detection” project is supported by the European Fund for Regional Development and brings together ScreenPoint Medical, Radboud University Medical Center (Radboud UMC), and Thirona. Together, these partners are developing AI tools to support the early detection of breast and lung cancer, aiming to improve clinical outcomes and streamline diagnostic workflows.

Project runtime: Jan 2025 – End of 2027

Within aiEMBRACE, ScreenPoint partners up with Netherlands Cancer Institute (NKI-AVL, Amsterdam), Memorial Sloan Kettering (MSKCC, NY), and Radboudumc (RUMC, Nijmegen) starting in Q4 2023 and will, for the next four years, advance AI-based technology to support women at elevated risk in their breast cancer patient journey from screening and diagnostics to treatment and follow up.

  • MRI breast cancer detection algorithms
  • Risk algorithms for future breast cancer development (MG and MR)
  • Cancer recurrence and prediction
  • Treatment response monitoring and prediction

Project runtime: Nov 2023 – Nov 2026